Island Pharmaceuticals Ltd (ASX:ILA) has completed dosing all subjects in its ISLA-101 Single Ascending Dose study, with the Safety Review Committee confirming all three doses was safe and well tolerated, based on a review of available preliminary data.
ISLA-101 is a well-known drug candidate, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.
Trial data in early 2024
Island CEO Dr David Foster said: “We are absolutely delighted to receive the news that ISLA-101 has been tolerated well by our study subjects and delivered safely to them. This was the study's primary objective.
“We have now completed all dosing in this study and are moving the blood samples to our analytical laboratory, where the levels of ISLA-101 in the blood will be examined and reported upon. We remain on track to report the data from the analysis in early 2024."
Fight against dengue virus
Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities.
Moreover, warming global climates are accelerating the presence of mosquito-borne viruses across the world.
Island’s Single Ascending Dose study is designed to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus, paving the way for the planned Phase 2a PEACH clinical trial.